Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Urges CMS to Monitor Patient Impact in Implementing the IRA

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

CLL Society joined fellow advocates in expressing the need for Centers for Medicare & Medicaid Services (CMS) to implement proactive guardrails around Part D health plans’ use of utilization management (UM) tools in light of the coming Part D redesign. In other words, when Part D plans become responsible for more of the drug cost that patients need in 2025, CMS must make sure those same plans do not alter or reduce patients’ access to those drugs.

Appropriate use of UM, full disclose and transparency on their policies, and sufficient education for patients on appeals processes will be critical. The impact on patients must be considered as the Inflation Reduction Act (IRA) is implemented.

Download the letter here.